When a Child’s Cancer Resists Treatment: The Potential of Immunotherapy

This encouraging presentation from pediatric hematologist-oncologist Michelle Hermiston, MD, PhD, director of UCSF’s pediatric immunotherapy program, focuses on relapsed acute lymphoblastic leukemia, the most common childhood cancer. Illuminating the physiology of harnessing the immune system to target cancer, she explains the benefits, risks and strategic use of CAR-T cell therapy, which has greatly improved the prognosis for kids in this population.